|
- 积分
- 244
- 威望
- 244
- 包包
- 616
|
本帖最后由 细胞海洋 于 2016-1-23 09:51 编辑 9 ?) S T' ?1 J5 h1 V- T
+ K( L6 k0 Y6 k+ [7 T目录7 g+ c9 H: j$ j0 k4 S
免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 4
9 T" T! F* a8 G: \1 m* d抗癌领域新突破 .................................................................................................................. 4' _/ J$ r" M7 |3 l6 f, b' y, s! b% f
600 亿美元市场空间 ............................................................................................................ 4 y/ Z: E* b- A% x" v! {9 c
免疫检查点的突破——PD-1 ....................................................................................................... 5
5 k& F. Z7 w+ i: k8 l9 nPD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 59 ]; [: K% R* \- U% L/ d- }8 J) F
PD-1 重磅产品频出 ............................................................................................................. 5" V! k' O# ?0 x# A4 K% A. y( r- j
在研PD-1 单抗全面开花 ....................................................................................................... 60 g7 s# x: g N/ G' y% x) ]! B! J
PD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 7+ r& j- V' _; c
PD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9
" z6 O! m: p a8 m1 J$ `PD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 9
$ U; a. E9 Q. h, E4 O sPD-1 市场前景广阔 ........................................................................................................... 10
9 M8 |& ?, \' p) |0 P, _/ n. }+ `免疫治疗热门靶点——PD-L1 ................................................................................................... 19
1 T5 I* e, \" Y. \- w- s! P2 \PD-L1 单抗免疫疗法原理 .................................................................................................... 19, \. M; g% z. ]5 {, d. ?% ?" W
PD-L1 单抗在研情况 .......................................................................................................... 19. a& h9 h& y) P. {
PD-L1 联用——多靶点治疗新选择 ......................................................................................... 19
, D6 ^( ?& K0 L6 Z m. q2 k2 g2 x, tPD-L1 未来市场 ............................................................................................................... 20$ r1 O- r/ R3 b0 }2 q
免疫治疗另一靶点——CTLA-4 .................................................................................................. 21
! f5 B" _6 U3 G6 v5 t, wCTLA-4 单抗免疫疗法原理 ................................................................................................... 21
& C v# W+ a5 tCTLA-4 单抗已上市产品 ..................................................................................................... 21
# N2 I- H, ~! t* QCTLA-4 在研产品.............................................................................................................. 22& F9 z- b2 c; |* W' w1 }
CTLA-4 的未来，联合用药是出路 .......................................................................................... 23
' ?) @: |$ f* ^相关公司简介 ........................................................................................................................ 24
7 k6 ~9 m1 X; X6 N: D# W君实生物 ........................................................................................................................ 24
: d/ b) l N, P( f) S恒瑞医药（确信买入评级） .................................................................................................. 25$ M) ~! f* W5 t5 F1 }6 p9 I& k- s
百时美施贵宝（BMS） ....................................................................................................... 26
0 h8 p4 D4 T- O& J# E ~4 }0 i/ \默克（Merck） ................................................................................................................ 27. w5 Y9 u3 h" K% ]$ `% V
7 B. a5 m& R. s8 l* [- }* A
9 b, a7 ~) D8 L G" d6 y: L+ ^[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 10
包包 + 20
查看全部评分
|
发表于 2016-1-23 09:08
发表于 2016-1-23 19:55
